Results 121 to 130 of about 108,380,509 (205)

Neurokinin-1 receptor antagonist aprepitant and radiotherapy, a successful combination therapy in a patient with lung cancer: A case report. [PDF]

Mol Clin Oncol, 2019
Muñoz M, Crespo JC, Crespo JP, Coveñas R.   +3 more
europepmc   +1 more source

Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial). [PDF]

Br J Cancer
Minatogawa H, Izawa N, Shimomura K, Arioka H, Iihara H, Sugawara M, Morita H, Mochizuki A, Nawata S, Mishima K, Tsuboya A, Miyaji T, Honda K, Yokomizo A, Hashimoto N, Yanagihara T, Endo J, Kawaguchi T, Furuya N, Sone Y, Inada Y, Ohno Y, Katada C, Hida N, Akiyama K, Ichikura D, Konomatsu A, Ogura T, Yamaguchi T, Nakajima TE.   +29 more
europepmc   +1 more source

Possible Mechanism of Action of Neurokinin-1 Receptors (NK1R) Antagonists [PDF]

Journal of Pharmacy and Pharmacology, 2017
null Özüm Öztürk, null Esin Aki-Yalcin, null Tugba Ertan-Bolelli, null Kayhan Bolelli, null Andry Nur-Hidayat, null Ozlem Bingol-Ozakpinar, null Filiz Ozdemir, null Ismail Yalcin   +7 more
openaire   +1 more source

Does neurokinin-1-receptor antagonist aprepitant diminish the efficacy of cyclophosphamide-based chemotherapy?

São Paulo Medical Journal
Carlos Eduardo Paiva, Bianca Sakamoto Ribeiro Paiva, Odair Carlito Michelin   +2 more
doaj   +1 more source

Differential effects of aprepitant, a clinically used neurokinin-1 receptor antagonist on the expression of conditioned psychostimulant versus opioid reward. [PDF]

Psychopharmacology (Berl), 2017
Mannangatti P, Sundaramurthy S, Ramamoorthy S, Jayanthi LD.   +3 more
europepmc   +1 more source

Neurokinin-3 receptor antagonists for vasomotor symptoms in menopause and breast cancer survivorship. [PDF]

CMAJ
Feng NL, Wilkinson AN, Delpero E, Srikanthan A.   +3 more
europepmc   +1 more source

Association of co-administration of neurokinin-1 receptor antagonists and dexamethasone with new-onset diabetes in patients receiving chemotherapy: a retrospective cross-sectional study using health claims database in Japan. [PDF]

Support Care Cancer
Ozawa Y, Suzuki S, Koinuma T, Yokokawa T, Ichimura T, Suzuki K, Hori Y, Imai S.   +7 more
europepmc   +1 more source

Correction: Liver Safety of the Dual Neurokinin‑1/‑3 Receptor Antagonist Elinzanetant. [PDF]

Drug Saf
Lewis JH, Andrade RJ, Larrey D, Horsmans Y, Anderson RA, Trajanovic M, Groettrup-Wolfers E, Zuurman L.   +7 more
europepmc   +1 more source

Opioid Peptide Hybrids as Multifunctional Analgesic Ligands: Emphasis on Intracellular Signaling. [PDF]

Pharmaceuticals (Basel)
Cecherz I, Waśkiewicz J, Dudek A, Polatyński D, Wtorek K, Piekielna-Ciesielska J.   +5 more
europepmc   +1 more source

Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy. [PDF]

Cancer, 2016
Hesketh PJ, Schnadig ID, Schwartzberg LS, Modiano MR, Jordan K, Arora S, Powers D, Aapro M.   +7 more
europepmc   +1 more source